Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. 2018;68(6):394–424.

[2]

Arnold M, Rutherford MJ, Bardot A, Ferlay J, Andersson TML, Myklebust TÅ, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 2019;20(11):1493–505. 10.1016/s1470-2045(19)30456-5

[3]

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA. 2019;69(1):7–34.

[4]

Henley SJ, Singh SD, King J, Wilson RJ, O’Neil ME, Ryerson AB. Invasive cancer incidence and survival-United States, 2012. MMWR. 2015;64(49):1353–8.

[5]

Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol. 2012;82(1):51–77. 10.1016/j.critrevonc.2011.04.012

[6]

Addington J, Freimer M (2106) Chemotherapy-induced peripheral neuropathy an update on the current understanding. Crit Rev 5:10 10.12688/f1000research.8053.1

[7]

Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nature reviews. Neurology. 2010;6:657.

[8]

Cavaletti G, Grp CIPS. Chemotherapy-induced peripheral neurotoxicity (CIPN): the dilemma of proper assessment. Nat Rev Neurol. 2018;12:657–66.

[9]

Colvin LA. Chemotherapy-induced peripheral neuropathy: where are we now? Pain. 2019;160(Suppl 1):S1–10. 10.1097/j.pain.0000000000001540

[10]

Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155(12):2461–70. 10.1016/j.pain.2014.09.020

[11]

Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176–81. 10.1016/s1053-4296(03)00031-6

[12]

Smith EML, Knoerl R, Yang JJ, Kanzawa-Lee G, Lee D, Bridges CM. In search of a gold standard patient-reported outcome measure for use in chemotherapy-induced peripheral neuropathy clinical trials. Cancer Control. 2018;25(1):1073274818756608. 10.1177/1073274818756608

[13]

Smith EML, Cohen JA, Pett MA, Beck SL. The reliability and validity of a modified total neuropathy score-reduced and neuropathic pain severity items when used to measure chemotherapy-induced peripheral neuropathy in patients receiving taxanes and platinums. Cancer Nurs. 2010;33(3):173–83. 10.1097/ncc.0b013e3181c989a3

[14]

Pachman DR, Barton DL, Watson JC, Loprinzi CL. Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther. 2011;90(3):377–87. 10.1038/clpt.2011.115

[15]

Molassiotis A, Cheng HL, Lopez V, Au JSK, Chan A, Bandla A, et al. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer. 2019;19(1):132. 10.1186/s12885-019-5302-4

[16]

Mendoza TR, Wang XS, Williams LA, Shi Q, Vichaya EG, Dougherty PM, et al. Measuring therapy-induced peripheral neuropathy: preliminary development and validation of the treatment-induced neuropathy assessment scale. J Pain. 2015;16(10):1032–43. 10.1016/j.jpain.2015.07.002

[17]

Kautio AL, Saarto T, Haanpää M, Leminen A, Kalso E, Kautiainen H. Oxaliplatin scale and National Cancer Institute-common toxicity criteria in the assessment of chemotherapy-induced peripheral neuropathy. Anticancer Res. 2011;31(10):3493–6.

[18]

Cavaletti G, Frigeni B, Lanzani F, Piatti M, Rota S, Briani C, et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst. 2007;12(3):210–5. 10.1111/j.1529-8027.2007.00141.x

[19]

Alberti P, Rossi E, Cornblath DR, Merkies ISJ, Postma TJ, Frigeni B, et al. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol. 2014;25:257–64. 10.1093/annonc/mdt409

[20]

Alberti P. Chemotherapy-induced peripheral neurotoxicity—outcome measures: the issue. Expert Opin Drug Metab Toxicol. 2017;13(3):241–3. 10.1080/17425255.2017.1258400

[21]

Abdi S, Dougherty PM. Chemotherapy-induced peripheral neuropathy: a challenge for clinicians. Oncology. 2016;30(11):1030.

[22]

Park SB, Kwok JB, Asher R, Lee CK, Beale P, Selle F, et al. Clinical and genetic predictors of paclitaxel neurotoxicity based on patient-versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial. Ann Oncol. 2017;28(11):2733–40. 10.1093/annonc/mdx491

[23]

Yeo F, Ng CC, Loh KWJ, Molassiotis A, Cheng HL, Au JSK, et al. Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy. Support Care Cancer. 2019;27(12):4753–62. 10.1007/s00520-019-04771-8

[24]

Pachman DR, Qin R, Seisler DK, Smith EML, Beutler AS, Ta LE, et al. Clinical course of patients with oxaliplatin-associated neuropathy: N08CB (Alliance). J Clin Oncol. 2014;32(15):3595. 10.1200/jco.2014.32.15_suppl.3595

[25]

Pachman DR, Qin R, Seisler DK, Smith EM, Beutler AS, Ta LE, et al. Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III Trial N08CB (Alliance). J Clin Oncol. 2015;33(30):3416–22. 10.1200/jco.2014.58.8533

[26]

Pachman DR, Qin R, Seisler D, Smith EM, Kaggal S, Novotny P, et al. Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer. 2016;24(12):5059–68. 10.1007/s00520-016-3373-1

[27]

Le-Rademacher J, Kanwar R, Seisler D, Pachman DR, Qin R, Abyzov A, et al. Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials. Support Care Cancer. 2017;25(11):3537–44. 10.1007/s00520-017-3780-y

[28]

Kaiser K, Lyleroehr M, Shaunfield S, Lacson L, Corona M, Kircher S, et al. Neuropathy experienced by colorectal cancer patients receiving oxaliplatin: a qualitative study to validate the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity scale. World J Gastrointest Oncol. 2020;12(2):205–18. 10.4251/wjgo.v12.i2.205

[29]

Soveri LM, Lamminmaki A, Hanninen UA, Karhunen M, Bono P, Osterlund P. Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy. Acta Oncol. 2019;58(4):398–406. 10.1080/0284186x.2018.1556804

[30]

Grisold A, Ackerl M, Surböck B, Giometto B, Grisold W. Multifocal neuropathy in vinorelbine treatment for breast cancer (P6.186). Neurology. 2017;88(16 Suppl):186.

[31]

Tamburin S, Park SB, Alberti P, Demichelis C, Schenone A, Argyriou AA. Taxane and epothilone-induced peripheral neurotoxicity: from pathogenesis to treatment. J Peripher Nerv Syst. 2019;24(Suppl 2):S40-s51.

[32]

Grammatico S, Cesini L, Petrucci MT. Managing treatment-related peripheral neuropathy in patients with multiple myeloma. Blood Lymphat Cancer. 2016;6:37–47. 10.2147/blctt.s91251

[33]

Thawani SP, Tanji K, De Sousa EA, Weimer LH, Brannagan TH 3rd. Bortezomib-associated demyelinating neuropathy—clinical and pathologic features. J Clin Neuromuscul Dis. 2015;16(4):202–9. 10.1097/cnd.0000000000000077

[34]

World Health Organization (2019) International Agency for Research on Cancer. WHO-IARC, Global Cancer Obsevatory Lyon, France. https://gco.iarc.fr/

[35]

Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics. CA. 2016;66(4):271–89.

[36]

Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36–46. 10.1056/nejmoa073149

[37]

Hall PS, Swinson D, Waters JS, Wadsley J, Falk S, Roy R, et al. Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): the GO2 phase III trial. J Clin Oncol. 2019;37(15 Suppl):4006. 10.1200/jco.2019.37.15_suppl.4006

[38]

Al-Batran S-E, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–57. 10.1016/s0140-6736(18)32557-1

[39]

Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci. 2019;20(6):1451. 10.3390/ijms20061451

[40]

Hana S, Irina V. Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy. Front Mol Neurosci. 2017;10:174. 10.3389/fnmol.2017.00174

[41]

Kroigard T, Schroder HD, Qvortrup C, Eckhoff L, Pfeiffer P, Gaist D, et al. Characterization and diagnostic evaluation of chronic polyneuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to quantitative sensory testing and nerve conduction studies. Eur J Neurol. 2014;21(4):623–9. 10.1111/ene.12353

[42]

Gebremedhn EG, Shortland PJ, Mahns DA. The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: a systematic review. BMC Cancer. 2018;18(1):410. 10.1186/s12885-018-4185-0

[43]

Park SB, Lin CSY, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC. Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist. 2011;16(5):708–16. 10.1634/theoncologist.2010-0248

[44]

Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve. 2004;29(3):387–92. 10.1002/mus.10559

[45]

Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol. 2007;25(16):2205–11. 10.1200/jco.2006.08.6652

[46]

de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938–47. 10.1200/jco.2000.18.16.2938

[47]

Briani C, Argyriou AA, Izquierdo C, Velasco R, Campagnolo M, Alberti P, et al. Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. J Peripher Nerv Syst. 2014;19(4):299–306. 10.1111/jns.12097

[48]

Branca JJV, Morucci G, Paternostro F, Gulisano M, Pacini A, Maresca M, et al. Oxaliplatin-induced blood brain barrier loosening: a new point of view on chemotherapy-induced neurotoxicity. Oncotarget. 2018;9(34):23426–38. 10.18632/oncotarget.25193

[49]

Fujita S, Hirota T, Sakiyama R, Baba M, Ieiri I. Identification of drug transporters contributing to oxaliplatin-induced peripheral neuropathy. J Neurochem. 2019;148(3):373–85. 10.1111/jnc.14607

[50]

Banach M, Juranek JK, Zygulska AL. Chemotherapy-induced neuropathies-a growing problem for patients and health care providers. Brain Behav. 2017;7:e00558. 10.1002/brb3.558

Showing 50 of 379 references

Cited By

247

Psychedelics; an untapped therapeutic niche: a narrative review in the future of cancer pain management

Maxine Min Chien Yap, Yasir Marwan Abdalla Omer · 2026

Medicine in Drug Discovery

Cancer pain: current practice and emerging targets

Yi Ye, Marcin Chwistek · 2026

British Journal of Pharmacology

Chemotherapy-induced polyneuropathy and neurofilaments

Olga A. Tikhonova, Evgeniia S. Druzhinina · 2026

Annals of Clinical and Experimental...

Cancer pain: molecular mechanisms and management

Wan-Li Wang, Yi-Hang Hao · 2025

Molecular Biomedicine

Hippophae rhamnoides L. (sea buckthorn) mediated green synthesis of copper nanoparticles and their application in anticancer activity

Pooja Dadhwal, Harish Kumar Dhingra · 2023

Frontiers in Molecular Biosciences

Late effects, long‐term problems and unmet needs of cancer survivors

Martina E. Schmidt, Siri Goldschmidt · 2022

International Journal of Cancer

Metrics

247

Citations

379

References

Details

Published: Oct 16, 2021
Vol/Issue: 9(2)
Pages: 385-450
License: View

Authors

Department of Medicine, Weill Cornell Medicine-Qatar, Doha, Qatar and New York, NY

U

Uazman Alam

Funding

Pain Relief Foundation

Cite This Article

Jamie Burgess, Maryam Ferdousi, David Gosal, et al. (2021). Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment. Oncology and Therapy, 9(2), 385-450. https://doi.org/10.1007/s40487-021-00168-y

Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment

You May Also Like